Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

RightBridge Ventures Group AB interim Q4 and full 2022 year financial report

SOLID FULL-YEAR GROWTH, EARNINGS WEIGHTED DOWN BY ONE – OFF, NON–CASH ITEMS and NEWLY ONBOARDED INVESTMENT.   GROUP RESULTS FULL YEAR 2022 Revenues. The Group’s net sales amounted to to 8,445KSEK (-).   Earnings. The Group’s net results for the full year were – 15 477KSEK (-3 042KSEK). Including non – cash affecting items. The Group’s adjusted net results, excluding the non–cash item of 1) the cost of the reverse takeover at -11 379KSEK and 2) goodwill amortization at -1 536KSEK,  amounted to -2 562KSEK (-3 042KSEK).   Earnings per share* amounted to SEK -0.36

Eurocine Vaccines discloses half-year report for July – December 2022

Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the half-year report for July to December 2022. Below is a summary of the report. The full report is available on Eurocine Vaccines’ website and as an attachment.   2022-10-01– 2022-12-31 (second quarter) · Results after tax for the quarter amounted to -6.2 MSEK (-5.3 MSEK) · Revenues for the quarter amounted to 1 KSEK (0 KSEK) · Earnings per share for the quarter amounted to -0.222 SEK (-0.373 SEK) 2022-07-01 – 2022-12-31 (first six months) · Results

“3D imaging is even better than a microscope”

When Dr Sirpa Pöyry makes a diagnosis, she is always confident in her findings. That’s because, more often than not, she has based her decision on a detailed 3D image of the area of interest. Today, the 3D images obtained with the clinic’s Planmeca Viso® G7 CBCT imaging unit are an indispensable part of her daily work and a tool she “would never go without.” It’s a common enough story. The patient complains of a tooth ache. Their treatment history shows the tooth has undergone root canal therapy some years ago. The panoramic image reveals an infection at the root. Will retreatment

Accedian and VMware Tighten Interoperability to Better Assure CSP Services Delivered Across Open RAN, MEC, and 5G Core

BARCELONA, Mobile World Congress 2023 – February 28, 2023 – Accedian , a leader in performance analytics, cybersecurity threat detection, and end-user experience solutions, today announced that its cloud-native Skylight service assurance solution is now interoperable with the VMware Telco Cloud  Platform . The validated integration will allow communications service providers (CSPs) to automatically onboard, catalog, and deploy containerized testing

Notice to the annual general meeting in Bonava AB (publ)

The shareholders of Bonava AB (publ), 556928-0380, ("Bonava"), are hereby invited to attend the annual general meeting, to be held on Monday, 3 April 2023 at 15.00, at Finlandshuset, Snickarbacken 4, Stockholm, Sweden. Registration for the annual general meeting will open at 14.30.The board of directors has decided that the shareholders may also exercise their voting right by postal voting, pursuant to article 13 in Bonava’s Articles of Association. Participation Shareholders who wish to attend the annual general meeting shall: · be listed in the shareholders' register maintained

Aker Solutions Wins Umbilicals Contract for the Agogo Field Development in Angola

February 28, 2023 – Aker Solutions has been awarded a sizeable[1] contract by Eni Angola S.p.A. – Sucursal de Angola, a subsidiary of Azule Energy Holdings Limited ("Azule Energy ”), to provide the dynamic and static subsea umbilicals for the Agogo field development located offshore Angola in the West Hub Area of Block 15/06.The contract includes the engineering, manufacturing and delivery of a complete umbilical system totaling about 36 kilometers of both dynamic and static subsea production control umbilicals including spares, as well as ancillary equipment and services. The umbilicals

Decreased number of shares and voting rights in Catena Media plc

Catena Media plc announces that the number of shares and voting rights in the company has decreased by 4,295,510 following the cancellation of ordinary shares which took place on 1 February 2023. As of 28 February 2023, the last trading day of the month, the number of shares and voting rights in Catena Media has decreased from 76,330,859 to 72,035,349 and share capital has decreased by EUR 6,443.27 to EUR 108,053.02.  Contact details for further information: Investor RelationsEmail: ir@catenamedia.com Peter Messner, Group CFOEmail: peter.messner@catenamedia.com This

Year-end report 2022 with interim report Q4

October - December 2022 Net sales increased by 21.3% Y-O-Y. Consolidated net sales ended at 69,611 (SEK 000s). EBITDA totaled -34,715 (SEK 000s). Operating profit, EBIT, was -65,535 (SEK 000s). Profit after tax was -67,491 (SEK 000s). Earnings per share was SEK -0.993. January - December 2022 Net sales increased by 21,9% Y-O-Y. Consolidated net sales ended at 257,162 (SEK 000s). EBITDA totaled -101,945 (SEK 000s). Operating profit, EBIT, was -190,808 (SEK 000s). Profit after tax was -218,299 (SEK 000s). Earnings per share was SEK -3.212.CEO's comments 2022 has been a demanding

Neste and ILLIG to showcase more sustainable solutions for thermoformed plastic packaging through demonstration cases

Neste Corporation, Press Release, 28 February 2023 at 9.00 a.m. (EET) Photo: Jürgen Lochner, CSO/CTO at ILLIG and Mercedes Alonso, Executive Vice President Renewable Polymers and Chemicals at Neste. Source: Neste   · Neste and ILLIG to build demonstration cases to showcase the benefits and feasibility of more sustainable solutions for thermoformed plastic packaging · The cooperation targets an acceleration in the shift away from fossil resources and to renewable and recycled materials Neste and ILLIG have entered into a strategic partnership to advance the use of more

Inhalation Sciences AB (publ) releases Year-End Report 2022

(Stockholm, Sweden, 28 February 2023) Inhalation Sciences AB announces that its Year-End Report for 2022 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/Summary of Year-End Report · Net revenue for the full year 2022 increased by 29% compared to 2021 · Sales for the full year 2022 increased by 74% compared to 2021 · Sales for Q4 2022 increased by 23% compared to the same period in 2021 · The company had an order backlog of SEK 9.1M in December 2022 compared to SEK 5M in the same

Notice of the Annual General Meeting of Cloetta AB (publ)

Shareholders of Cloetta AB (publ), reg. no. 556308-8144, are hereby invited to attend the Annual General Meeting, to be held on Tuesday, 4 April 2023 at 3.00 p.m. CET at Courtyard by Marriott, Rålambshovsleden 50 in Stockholm, Sweden. Registration will commence at 2.00 p.m. CET.The Board of Directors has resolved that shareholders may also exercise their voting right at the Annual General Meeting by postal voting pursuant to the provisions in the Articles of Association of Cloetta. Right to attend the meeting and noticeShareholders who wish to participate in the Annual General Meeting

Q4 and full year report January – December 2022

Significant increase of operating profit in 2022Highlights fourth quarter 2022 · Gross collections amounted to EUR 16.4m (17.6)* · Net collections amounted to EUR 14.2m (15.0)* · Cash EBITDA amounted to EUR 10.2m (12.7)* · Net loss for the period of EUR 0.2m (profit 1.0)* · Gross ERC at the end of December 2022 was EUR 283m (297 at December 2021) · Cash at the end of December 2022 was EUR 52.3m (62.8 at December 2021) Highlights full year 2022 · Gross collections amounted to EUR 70.8m (56.9)* · Net collections amounted to EUR 61.2m (47.6)* · Cash EBITDA

Q4 and full year report January – December 2022

Significant increase of operating profit in 2022Highlights fourth quarter 2022 · Gross collections amounted to EUR 16.6m (18.7)* · Net collections amounted to EUR 14.4m (15.3)* · Cash EBITDA amounted to EUR 10.6m (11.8)* · Net profit for the period of EUR 0.1m (0.1)* · Gross ERC at the end of 2022 was EUR 284m (299 at December 2021) · Cash at the end of 2022 was EUR 52.6m (65.5 at December 2021) Highlights full year 2022 · Gross collections amounted to EUR 71.9m (61.7)* · Net collections amounted to EUR 62.3m (50.1)* · Cash EBITDA amounted to EUR 50.6m (38.

Esmaeilzadeh Holding publishes year-end report for 2022

“We are leaving an eventful year behind us that has been formative for EHAB and our investment portfolio. We have taken methodical strides in establishing ourselves as an entrepreneurial investment company with profitability and long-term sustainability as its basic idea. This is substantiated by the journeys our portfolio companies have been through, which have resulted in new levels of maturity, size, and stability. We head into the new year with strong confidence from the capital market, a well-proven strategy, and the necessary organisation for implementing our plans for 2023.” - Saeid

Year-end report and interim report for the period 1 October 2022 – 31 December 2022

published at 08:00 on 28 February 2023 Wicket Gaming AB (”Wicket Gaming” or the ”Company”) publishes interim report for the period 1 October 2022 – 31 December 2023.Summary of the period The Group arose during the fourth quarter, and consequently no comparison is made with the corresponding period in the previous year. The information for the period 01/01/2022 – 31/12/2022 includes the whole year for the Parent Company and the fourth quarter for the Group. Fourth quarter 01/10/2022 – 31/12/2022 (Group) · Net sales: SEK 6,883 thousand. · Earnings before interest, taxes,

Year-end report 2022

MindArk PE AB (publ) ("MindArk", the "Company") hereby announces that the Company's year-end report for 2022 and interim report for the fourth quarter of 2022 have now been published.Comment from CEO Henrik Nel Jerkrot: “It is with great pleasure that with our first financial report as a listed company, we have had a record quarter in terms of net revenue. During the quarter, we have been working extensively on  the graphics engine transition to Unreal Engine 5. However, we have been careful not to let this affect the user experience or content creation in the current Entropia Universe.

Mirovia Nordics AB (publ) publishes year-end investor report 2022 - Successful launch of the European expansion

Mirovia Nordics AB (publ) ("Mirovia" or the "Group") ended the year with a solid 9.8% increase in pro forma turnover from SEK 978m to SEK 1 073m, compared to 2021. The pro forma EBITDA increased at a similar pace, at 9.9%, from SEK 182m to SEK 200m.Mirovia is continuing to grow organically, despite these exceptional times and the Group has been able to do so while maintaining their profitability. Mirovia is well diversified with its strategy and consequent focus on business-critical software solutions. Significant efforts were made in this last quarter to successfully onboard and integrate

Qred’s growth continued through 2022 - increased operating income by 49%

Qred continues to grow, as operating income increased by 46% to SEK 154.5m compared to the same period last year. The number of active users increased 23% to 16,517 by the end of the quarter. Values for the same period the previous year are stated within brackets. October - December 2022 · The number of active monthly users increased by 23% to 16 517 (13 483) · Operating income increased by 46% to SEK 154.5m (105.7) · Commission income increased by 54% to SEK 102.3m (66.3) · Interest income increased by 27% to SEK 65.0m (51.4) · Operating profit amounted to

TOMRA: Key information relating to the proposed cash dividend to be paid by TOMRA Systems ASA

· Dividend amount: NOK 1.80 per share · Declared currency: NOK · Last day including right: 27 April 2023 · Ex-date: 28 April 2023 · Record date: 2 May 2023 · Payment date: On or about 9 May 2023 · Date of approval: 27 April 2023 This information is published in accordance with the requirements of the Continuing Obligations. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Mirovia Nordics AB (publ) publishes formal year-end report 2022

Mirovia Nordics AB (publ) publishes formal year-end report 2022Quarter 4: October 1 – December 31 · Operating revenue amounted to SEK 351,276k (SEK 82,212k). · Operating profit amounted to SEK 75,938k (SEK 1,364k). ·  Profit for the period amounted to SEK 22,076k (SEK -9,666k). Full year: January 1- December 31 · Operating revenue amounted to SEK 746,540k (SEK 186,215k). · Operating profit amounted to SEK 110,133k (SEK 16,027k). · Profit for the period amounted to SEK 9,975k (SEK -10,720k). · Cash flow from operating activities amounted to SEK -15,956k (SEK -7,

Year-end Report 2022

Increased sales in fourth quarter and full year. At the beginning of 2022, we were finally able to see the end of the COVID-19 pandemic and have gradually been able to accelerate our activity levels in terms of participation at fairs and congresses and, not least, by being able to have meaningful meetings with our customers. The positive sales trend we have seen during the year continued in the fourth quarter and sales rose by 38 percent to SEK 9.4 (6.8) million. Strengthened by this development, we are now approaching 2023 with great energy and even sharper focus. October – December

Year-end report 2022

Fourth quarter: October - December 2022 · Revenues from the gaming operation amounted to mSEK 8.0 (8.4), corresponding to a decrease of 4 percent · B2B revenues amounted to mSEK 5.1 (3.0), an increase of 70 percent · B2C revenues amounted to mSEK 2.9 (5.4), a decrease of 45 percent · Total revenues amounted to mSEK 8.0 (10.1) · EBITDA decreased to mSEK -10.7 (-37.3) · Net result decreased to mSEK 0.0 (-39.1) · Earnings per share amounted to SEK 0.00 (-1.73) · Signed agreements with Apple iSports and Cartola Express Full year 2022 · Revenues from the gaming

DanCann Pharma A/S publishes Q4-2022 report

COPENHAGEN, Denmark, 28 February 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the fourth quarter of 2022. The Q4-2022 report is available as an attached document to this press release and at www.dancann.com.SUMMARY: GROUP KEY FIGURES Q4 2022 KDKK 01/01/22 01/01/21 01/10/22 - 31/12/22 01/10/21 - 31/12/21 - 31/12/22 - 31/12/21 Net sales 5.707  874  2.101  874 Operating

There are no items matching the current filter
There are no more items matching the current filter
Back to top